Effect of race on outcome of white and black children with acute myeloid leukemia: the St. Jude experience

Pediatric Blood & Cancer
Jeffrey E RubnitzRaul C Ribeiro

Abstract

The association between race and outcome of treatment for childhood acute myeloid leukemia (AML) has not been adequately studied. We compared the clinical characteristics, biological features, and outcomes between white and black children with AML who were treated on five consecutive clinical protocols (1980-2002) at St. Jude Children's Research Hospital. We used proportional hazards modeling to investigate the relation between race and outcome. We observed no statistically significant differences between the 229 white and 58 black patients in clinical characteristics, FAB subtype, cytogenetic features, or outcome. There were no significant differences in event-free survival (EFS) or overall survival (OS) between the two race groups in individual clinical trials or in all studies combined. For the study group as a whole, the 5-year survival estimate was 39.2% +/- 3.6% for white patients and 33.8% +/- 6.5% for black patients. However, on our most recent trial (AML-97), there was a trend towards inferior outcome among black patients: the 5-year survival estimates were 55.6% +/- 12.3% and 27.3% +/- 13.5% for whites and blacks, respectively. Although we detected no differences in treatment outcome between white and black children w...Continue Reading

References

Feb 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G V DahlF L Johnson
Jul 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D KalwinskyG V Dahl
Feb 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B H PollockS B Murphy
Jan 10, 2001·Cancer·C J BradleyC Roberts
Jun 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R A KranceR C Ribeiro
Apr 23, 2002·JAMA : the Journal of the American Medical Association·Peter B BachColin B Begg
Oct 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kristine R CrewsRaul C Ribeiro
Oct 16, 2003·JAMA : the Journal of the American Medical Association·Ching-Hon PuiWilliam E Evans
Oct 16, 2003·JAMA : the Journal of the American Medical Association·Nina S Kadan-LottickJames G Gurney
Feb 21, 2004·Blood·Mikkael A SekeresUNKNOWN Cancer and Leukemia Group B
Apr 9, 2004·The New England Journal of Medicine·Ching-Hon PuiJames R Downing

❮ Previous
Next ❯

Citations

Sep 14, 2012·Cancer Causes & Control : CCC·M I PatelK F Rhoads
May 29, 2008·Current Treatment Options in Oncology·Jeffrey E Rubnitz
Jul 24, 2010·Current Hematologic Malignancy Reports·Mohamed RadhiAlan Gamis
Mar 26, 2011·Journal of Pediatric Hematology/oncology·Ester Augusta Lima Vinhas MarquesNorma Lucena-Silva
May 17, 2011·Journal of Pediatric Hematology/oncology·Silke SwinnenIngele Casteels
Nov 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tara O HendersonSusan L Cohn
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ching-Hon PuiAmar Gajjar
Feb 2, 2010·Hematology/oncology Clinics of North America·Jeffrey E RubnitzFranklin O Smith
Feb 5, 2008·Pediatric Clinics of North America·Jeffrey E RubnitzFranklin O Smith
Dec 16, 2006·Pediatric Blood & Cancer·Antonio Pérez-MartínezLuis Madero López
Feb 18, 2011·Pediatric Blood & Cancer·Smita Bhatia
Mar 11, 2015·Pediatric Blood & Cancer·Paula AristizabalMaria E Martinez
Apr 3, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Nirali N ShahAllen R Chen
Sep 12, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Kyung Im KimJung Mi Oh
Nov 10, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·K Scott BakerJ Douglas Rizzo
Jan 20, 2015·Journal of Pediatric Surgery·Mary T AustinLinda S Elting
Nov 12, 2016·Clinical Lymphoma, Myeloma & Leukemia·Syed Sameer NasirMike G Martin
Nov 20, 2016·American Journal of Hematology·Lena E WinestoneRichard Aplenc
Mar 8, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Monika L MetzgerScott C Howard
Aug 14, 2019·International Journal of Cancer. Journal International Du Cancer·Anniina KyrönlahtiMervi Taskinen
Dec 10, 2019·Current Opinion in Pediatrics·Caitlin W Elgarten, Richard Aplenc
Jun 2, 2021·American Society of Clinical Oncology Educational Book·Paula AristizabalKira Bona
May 19, 2021·Journal of Pediatric Hematology/oncology·Maria I CastellanosHamisu M Salihu
Jan 7, 2022·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Abdelrahman H ElsayedJatinder K Lamba

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.